GlassScriptPhysician profile
Jennifer M Chen
NPI 1932587201
$3,653.56
in general payments reported to CMS, 2019-2025
32 companies · $642 in 2025
The $642 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $271 · 2021: $758 · 2022: $636 · 2023: $425 · 2024: $489 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.80 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Exeltis, USA INC. | $278.11 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $230.75 | 2021-2024 | Twirla |
| Evofem Biosciences, INC. | $229.97 | 2021-2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $216.35 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $191.43 | 2020-2024 | Novasure, Acessa Provu System |
| Therapeuticsmd, INC. | $179.20 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $166.94 | 2021-2025 | |
| Sage Therapeutics, LLC | $141.14 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $106.14 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $77.23 | 2019-2020 | |
| Organon LLC | $70.04 | 2022-2025 | Nexplanon |
| Lilly USA, LLC | $65.32 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $64.50 | 2019-2025 | Wegovy, Saxenda |
| Millicent US INC | $59.75 | 2024-2025 | Intrarosa, Femlyv, Femring |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $54.66 | 2024 | Ova1 |
| Sumitomo Pharma America, INC. | $52.36 | 2023-2024 | Myfembree |
| Supernus Pharmaceuticals, INC. | $44.15 | 2025 | Qelbree |
| Myovant Sciences INC. | $43.50 | 2021-2022 | |
| Scynexis, INC. | $41.60 | 2022 | |
| Astellas Pharma US INC | $33.77 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $33.69 | 2020-2021 | |
| Lupin INC. | $32.97 | 2019-2020 | |
| Pfizer INC. | $29.66 | 2025 | |
| Medicem INC. | $23.25 | 2020 | |
| Ascend Therapeutics US, LLC | $22.73 | 2022 | |
| Shield Therapeutics INC | $20.44 | 2023 | Accrufer |
| Ferring Pharmaceuticals INC. | $17.96 | 2019 | |
| Avion Pharmaceuticals | $17.82 | 2023 | Balcoltra |
| Becton, Dickinson and Company | $16.47 | 2022 | |
| Dysis Medical, INC. | $13.48 | 2020 | |
| Mission Pharmacal Company | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.